Peptic ulcer refers to the group of gastrointestinal disorders such as gastritis, gastric ulcers, and Duodenal ulcers or gastroesophageal reflux disease (GERD). Drugs used for the treatment of peptic ulcers include those that reduce gastric ulcer secretion, such as PPI and H2 receptor antagonists and acid neutralization agents such as antacids and antibiotics against H. pylori infection. However, these drugs are often used in combination for effective treatment.
The global peptic ulcer drugs market is estimated to account for US$ 45,951.2 Mn in terms of value by the end of 2027
Factors driving the growth of the global peptic ulcer drugs market include growing prevalence of peptic ulcers, increasing adoption of peptic ulcer drugs over surgery, R&D stimulation through government policies, increasing number of generic manufacturers of peptic ulcer drugs, changes in disease management, etc.
Furthermore, factors such as growing prevalence of stress-induced ulcers due to changing lifestyle and diet, increasing smoking rate, and progressive population of geriatrics are anticipated to promote the expansion of the global peptic ulcer drugs market size over the forecast period of 2019 to 2027.
However, the side effects of peptic ulcer drugs, poor pipeline productivity, and changes in pricing policies of drugs are factors expected to hamper the growth of the global peptic ulcer drugs market over the coming years.
Key players in the market can focus on personalized treatment and management of patients suffering from PUD in order to enhance their market share. For instance, in July 2019, in a study published in the Journal of Clinical Medicine (MDPI), researchers from Institute of Medical Microbiology, Switzerland, concluded that next generation sequencing technology may facilitate rapid monitoring of virulence determinants in H. pylori, which may prove beneficial in personalized treatment and management of patients suffering from PUD.
Moreover, high doses of nonsteroidal anti-inflammatory drug (NSAIDs) is associated with risk of recurrent PUD. Therefore, market players may focus on R&D in H. pylori eradication therapy as it has the potential to reduce the risk of recurrent PUD among NSAID users.
No comments:
Post a Comment